Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Jun 15;116(12 Pt 1):967-73.
doi: 10.7326/0003-4819-116-12-967.

Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels

Affiliations
Clinical Trial

Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels

C J Bagatell et al. Ann Intern Med. .

Abstract

Objective: To investigate the role of physiologic levels of testosterone in the control of lipoproteins in healthy men.

Design: A double-blind, randomized study.

Setting: A university community.

Participants: Fifteen healthy men, ages 20 to 36 years.

Intervention: We induced acute, reversible hypogonadism in five normal men by administering daily subcutaneous injections of the gonadotropin-releasing-hormone (GnRH) antagonist, Nal-Glu, for 6 weeks. Another group of five normal men received Nal-Glu plus weekly injections of testosterone enanthate, 100 mg/wk, thereby maintaining normal serum testosterone levels. Five additional men received placebo injections.

Measurements: Plasma lipids, including high-density lipoprotein (HDL) subfractions HDL2 and HDL3, apoprotein A1, and serum levels of gonadotropins, estradiol, and testosterone were measured before, during, and after treatment.

Results: At the end of the treatment period, HDL cholesterol levels in men receiving Nal-Glu increased by 26% (95% CI, 18% to 34%; P less than 0.05). Levels of HDL2, HDL3, and apoprotein A1 increased by 63% (CI, 16% to 110%), 17% (CI, 3% to 31%), and 17% (CI, 5% to 29%), respectively (P less than 0.05 for each parameter). Total cholesterol increased by 12% (CI, 2% to 22%). Low-density lipoprotein (LDL) cholesterol and triglyceride concentrations did not change. No statistically significant changes occurred in any lipid measurement in men receiving Nal-Glu plus androgen replacement or placebo (P greater than 0.05).

Conclusions: Experimental hypogonadism induced by administration of a GnRH antagonist results in a statistically significant increase in HDL cholesterol, including HDL2 and HDL3. These effects are most likely due to decreased androgen levels because they are reversed by administration of antagonist together with testosterone. Our results imply that androgen levels in the normal adult male range have a suppressive effect on HDL cholesterol concentration and may contribute to the increased risk for coronary artery disease in men.

PubMed Disclaimer

Comment in

  • SI units and the Friedewald formula.
    Massé J. Massé J. Ann Intern Med. 1992 Nov 15;117(10):876. doi: 10.7326/0003-4819-117-10-876_1. Ann Intern Med. 1992. PMID: 1416568 No abstract available.

Similar articles

Cited by

Publication types

Substances

LinkOut - more resources